Clinical data regarding the activity of other MKIs (sorafenib, sunitinib, ponatinib, alectinib, nitedanib and regorafenib) in RET fusion-positive NSCLC are lacking or have been reported in smaller experiences, case reports and in patients included in the large retrospective series already cited [45], in which MKIs were administered in various line of systemic therapy. The gene discussed is RET; the disease is non-small cell lung carcinoma.